Promising clinical durability observed with 80% of wet AMD treated eyes and 78% of DME treated eyes extended to four months or longer without receiving retreatment
Strong anti-VEGF efficacy continues to be observed across the major retinal vascular diseases
Encouraging safety profile with zero cases of intraocular inflammation after 300+ doses in 100+ patients
PR Newswire
PALO ALTO, Calif., Oct. 11, 2019
